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The TRH Stimulation Test in Alzheimer's Disease 
and Major Depression: 
Relationship to Clinical and CSF Measures 
Susan E. Molchan, Brian A. Lawlor, James L. Hill, 
Alan M. Mellow, Candace L. Davis, Rick Martinez, 
and Trey Sunderland 
A blunted thyroid-stimulating hormone ~TSH) response to exogenous thyrotropin-releasing 
hormone (TRI-I) has been reported to occur consistently in patients with major depression 
and less consisten@ in patients with Alzheimer" s disease fAD). In this study we compared 
the TSH response to TRH in a large group (n = 40) of AD patients~ elderly patients 
with major depression (n = 17), and age-matched controls (n = 14) w further char- 
acterize how it may relate to clinical variables, baseline @roid function tests, and 
cerebrospinal fluid measures. Comparisons of TRH stimulation test response across aH 
three groups revealed that patients with major depression had lower ~imulated TSH 
levels (AmaxTSH) (p < 0.02) and higher (though still within norma! limits)mean thyroxine 
(T¢) levels (p < 0.05) than the AD patients or controls. AD patients with a blunted TSH 
response had a significantly higher mean free 7"4 fFT4) level (p < 0.03) and tended to 
be more severely demented (p < 0.01) than thos,~ with a nonblunted response. 
Introduction 
Neuroendocrine tests such as the dexamethasone stimulation test and the thyrotropin- 
releasing hormone (TRH) stimulation test have been examined in patients with v~ous 
neuropsyclfiau--ic diso~uers as a ~ssible window to ',,he underlying ne~o_t,-ansmjt3_er path- 
ophysiology (Loosen 1987). This idea is complicated by the interacting regulatory and 
feedback mechanisms present in the body for each neuro~smitter and each associated 
hormonal signal (Loosen 1987). Still, it is felt that neuroendocrine tests may give us 
clues regarding the pathophysiology and course of c e ~ n  disorders or sy_m_ptoms~ par- 
ticularly in delineating different biological subgroups of neuropsychiatric disorders. The 
study of neuroendocrine abnormalities in Alzheimer's disease (AD) may be of particular 
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interest, in that alterations in neurotransmitters and their metabolites have already been 
studied extensively in plasma, CSF, and postmortem brains, making AD one of the most 
well-characterized neuropsychia~c illnesses in terms of specific pathology and associated 
neurochemical changes (Perry 1987). 
A blunted thyroid-stimulating hormone (TSH) response to intravenously administered 
TRH has been reported to occur in 25%-75% (depending on the cutoff value used to 
define a blunted TSH response) of patients with major depression (Loosen 1987). Patients 
with major depression and AD often have overlapping clinical symptoms (Reding et al 
1985; Reifler et al 1916), and studies of the TRH stimulation test in AD have shown that 
up to 47% of patients have a blunted TSH rresponse (Sunderland et al 1985; Thomas et 
al 1987). Other researchers have reported no blunting of the TSH response to TRH in 
AD patients (El Sobky et al 1986; Peabody et al 1986; Franceschi et al 198~; Lampe et 
al 1988; Warner et al 1990). To help clari~ the ongoing scientific debate concerning the 
TRH stimulation test in AD, we studied the TSH response to TRH in a large group of 
AD patients, a group of elderly patients with major depression, and age-matched normal 
controls. Given the substantial number of AD subjects in this study, we also examined 
the TSH response with reference to clinical and biological characteristics including base- 
line thyroid function tests (TFTs), CSF monoamine metabolites, and CSF somatostatin- 
like immunoreactivity (SLI). 
Subjects and Methods 
Fifty patients with probable AD, 21 older patients diagnosed with major depression, and 
18 age-matched controls participated in the study. Probable primary degenerative dementia 
of the Alzheimer type and major depression were diagnosed according to DSM-IIIR 
criteria (American Psychiatric Association 1987). In addition, patients diagnosed with 
major depression had a history of prior depressive episodes, had no significant cognitive 
impairment, and recovered after treatment with antidepressant medication or electrocon- 
vulsive therapy. Some of the AD patients had prior or concurrent depressive symptoms, 
but the dementia was established as the primary diagnosis. Significant medical problems 
were ruled out in all patients and controls by physical examination and laboratory tests. 
Normal controls were screened to exclude any personal or significant family history of 
medical, cognitive, or psychiatric disorder. Controls were recruited from the community 
and paid for their participation. All subjects gave written informed consent prior to 
e,- ..... e,~,,,-,,, ,n ,,,e ~,uuy ttt,~ AD patients, a relative also signed the consent form). The 
AD and major depression patients were studied during hospitalization at the NIMH and 
the normals as outpatients; all tests and ratings were done within a 3-week period. Subjects 
were free of all psychotropic medications for at least 3 weeks prior to participation. 
The TRH stimulation test was done between 8:30 and 10:30 AM after an overnight 
fast. An 18-gauge catheter was inserted into an antecubital vein and baseline blood samples 
were collected through the catheter at least 20 min after IV insertion. After collection of 
the - 15 and 0 time point samples, 0.5 mg of TRH (Protirelin) was administered as an 
IV bolus. Subsequent blood samples were collected 15, 20, 30, and 45 min following 
the TRH injection. TSH levels were determined by double-antibody radioimmunoassay 
(RIA) by the NIH Clinical Center laboratory (normal range 0.4-4.6 p.IU/ml). The coef- 
ficients of variation for this assay for low, midrange, and high concentrations are 6.2%, 
5.1%, and 5.0%, respectively. Baseline TFTs and TSH levels were measured in serum, 
on the day in which they were collected. Triiodothyronine ('1"3) (normal range 88-162 
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Table I. Clinical Data on AIzheimer's Disease Patients (n = 40~ 
Clinical measure Mean _- SD 
Illness duration ¢yr) 3 8  _ 2 I 
Dementia severity 
Clinical Dementia Rating 17 : 0 7  
Global Deterioration Scale 4~5 _* 0 9  
Wechsler Memory Scale 68~0 ± 13~0 
DMAS (17 ilemV |9~5 _-z- |0~5 
Bunney-Hamburg Global Scales 
Depression 3 4  ~_ 17 
Anxiely 4 2  _- [ 9  
Sadness 4~6 *_ 2~2 
Anger 2.7 -.- ! 8 
Psychosis J.7 _- | .3 
"Dementia Mood Assessment ScMe. 
ngJdi) and free T~ (FL)  (normal range 1.0-2.1 ng/dl) were measured by RIA, and 
thyroxine (T4) (normal range 5.0-10.0 ttg/dl) by fluorescence polarization immunoassay. 
Dementia severity was rated using the Clinical Dementia Rating (CDR) (Hughes et al 
1982) and the Global Deterioration Scale (GDS) (Reisberg et al 1982). "Fne degree of 
depression in the AD patients was evaluated using the Dementia M ~  Assessment Scme 
(DMAS) (Sunderland et al 1988a, 1988b), a 24-item scale, the first 17 of which were 
designed to measure depression in dementia patients; the last 7 items measure cognitive 
and functional impairment. The Bunney-Hamburg Global Behavior',d Rating Scales were 
used to evaluate aspects of behavior, mood, and impairment (Burmey and Hamburg 1963; 
Sunderland et al 1988a) in both patient groups. The depressed patiems were also evaluated 
with the Hamilton Depression Scale (Hamilton 1960). 
Lumbar punctures (LPs) were done between 8:00 and 9:00 AM, in the lateral decubims 
position, after an overnight fast. Subjects were on bed rest prior to the LP, except for 
voiding. CSF from early aliquots was frozen at -70°C and later used for measurement 
of the neurotransmitter me~bolites 3-methoxy-4-hydroxyphenylglycol ( M H ~ ) ,  5-hy- 
droxyindoleacetic acid (5-HiAA), and homovanillic acid (HVA), as described elsewhere 
(Scheinen et al 1983). The 26th ml of collected CSF was in~ediately frozen without 
preservatives on dry ice and ~tored at -70°C for later measurement of SLI by ~ ,  as 
l U ~ . , ~ l . , i | t , ¢ ~ , l  ~ , - . . a n ~ w l l i j l . , i ~ l ,  , L ~  : i a  . .  a J v v  . 
Data Analysis 
For comparisons among subject groups, data were analyzed using subjects with completely 
normal baseline TFTs (Table 1), unless otherwise specified. Subjects with TFTs outside 
of the normal range were excluded in order to standardize conditions for the analysis of 
TRH stimulation test results as much as possible, so that results would better reflect 
changes related to the illnesses being studied, rather than primary thyroid conditions, in 
view of the high prevalence of thyroid abnormalities in the elderly (Targum et al 1989). 
Between-group differences in age, baseline TFTs, and the mean maximum increase of 
TSH (AmaxTSH) from the mean baseline value (the sum of the values at the - 15 and 
0 time points, divided by 2) were evaluated using one-way analysis of v~ance  (ANOVA) 
and t~st hoc t-tests. 
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The time course of the TSH response to TRH was compared among groups using 
repeated-measures ANOVA, followed by one-way ANOVAs accompanied by post hoc 
t-tests at each time point. Also, the area under the curves (AUC) of the TSH response 
to TRH among subject groups was compared using one-way ANOVA and post hoc t- 
tests. Missing data points (2%) for the time course and AUC analyses were estimated by 
line~ interpolation. 
"Blunted" when used in the text refers to AmaxTSH levels of <~7 IxlU/ml, unless 
otherwise specified. Fisher's exact test was used to compare the rate of blunted responses 
(using cutoff values of both <~7 ~IU/ml and ~<5 glU/ml) a ~ n g  diagnostic groups (Loosen 
1987). One-tailed statistics were used based on prior studies showing either a blunted 
response, or no difference from normals in AD and depressed patients. One-way ANOVA 
and post hoc t-tests were used to compare mean AmaxTSH between genders, within and 
among diagnostic groups. Differences in baseline TITs, TSH response, and clinical 
variables were examined between genders and between blunters and nonblunters within 
each diagnostic group by t-tests (two-tailed). A correlation (Pearson's) matrix was gen- 
erated to explore possible relationships between the clinical and biological variables. 
Results 
Ten AD patients had abnormal baseline T ~ s ;  mos t  of these had a slightly elevated 
baseline TSH. Two depressed patients and two normal controls had an elevated baseline 
TSH, and two in each of these groups had an elevatexl FT4. Therefore, 10 of 50 (20.0%) 
AD, 4 of 21 (19.0%) depressed, and 4 of 18 (22.2%) control subjects had baseline TFT 
abnormalities, and were therefore excl~ed from further analyses. These numbers are 
consistent with prior studies showing that the prevalence of thyroid ab,lormalities is not 
significantly different between AD patients and controls (Lawlor et al 1988). 
When all subjects (including those with abnormal baseline TFI's) are included, the 
rates of blunting are as follows: 11 of 50 (22.0%) of the AD patients (p < 0.26 different 
from normals), 9 of 21 (42.9%) of the depressed patien~ (p < 0.03 different from 
normals, p < 0.07 different from AD patients), and 2 of 18 (11.1%) of the normals. 
When those subjects with normal TFTs were compared (Table 1), the group of patients 
with major depression had a higher rate of TSH blunting than the normals (7 of 17 [41%] 
versus 1 of 14 [7%], p < 0.04). The rate of blunting in the AD group (11 of 40, or 
27.5%) differed from normais at a trend level of significance (p < 0.10) and did not 
differ from that of the depressed group (p < 0.24) (Table 3). When a cutoff of ~<5 p.IU/ 
ml was used for AmaxTSH, 6 of 40 (15%) (4 men, 2 women) of AD patients (p < 0.10 
different from normais), 5 of 17 (29.4%) (4 men, 1 woman) of depressed patients (p < 
0.04 different from normals, p < 0.18 different from AD patients), and no norrnals had 
a blunted response. 
The major depression patients had a significantly lower mean AmaxTSH (F[2, 70] = 
4.96, p < 0.01) than both the AD patients (p < 0.003) and the elderly controls (p < 
0.02) (Table 2). Repeated-measures ANOVA revealed an overall significant difference 
between subject groups (group x time interaction F[2.6, 88.5] = 4.38, p < 0.01) for 
the time course of the TSH response to TRH shown in Figure 1. This overall difference 
resulted because stimulated TSH levels in the depressed group were significantly lower 
at all time points than those of both the AD and normal subjects, who did not differ from 
each other. The trend towards a significant difference in AUC (F[2, 68] = 2.94, p < 
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Table 2. Demographic and Biological Data on Patients and Normal Controls 
Maj~ N ~  
Ahv.heimer's Disease Depression C~troh 
Variable (n = 40) {n = 17) (n = 14) 
Age (yr) 64.2 _ 7.8 65~8 ± 8.| 62°3 ~ 8.t 
Gender 25M, 15F 8M, |OF 9M, 6F 
Amax TSH ~p.IU ml) 12.8 ~ 6.1 7.0 _ 6.7 '~ |2.5 ± 6.7 
Baseline TSH (p.IU:mi) 2.6 ± 1.2 2.3 _* | .2 2.7 ± 1.2 
Total 'i"4 (p.g/dl) 7.8 ± 100 8.9 ± |.3 '~ 7.5 ",_'_ |°4 
Free T4 (ngMl) i.4 _*- 0.4 |°7 ± 0°4 ~ 1.4 ± 0.4 
11"3 (ngMl) 125.8 _ 25.5 12Z4 : 25.5 t19.5 _* 26.4 
"p < 0.05 different from Alz~mter ' s  patients and comroh. 
0.06)  also resulted because the depressed patients had a ~maller area than ~ t h  the A D  
and normal subjects. 
Table 2 summarizes  mean baseline TFT data for all subjects. Baseline TFT dat~ on 
patients with a blunted as compared with a nonblunted response is summarized in T~ ble 
3. Table 4 summarizes  T S H  response and baseline TFTs by gender.  C o m ~ s o n  of  mean 
AmaxTSH of  female subjects among diagnosuc groups revealed statistically significant 
differences (F[2,  26] = 3.43,  p < 0.05);  paired comparisons were significant o ~ y  
between the depress_ed ~_qd control groups (p  < 0.05)  (Table 4). S i ~ f i c a n t  differences 
of  AmaxTSH were also found among diagnostic groups of  male  subjects ( ~ 2 ,  391 = 
5 .56,  p < 0.008),  with paired comparisons significant only between the AD and depressed 
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Figure 1. TSH responses to TRH across time in AD patients, depressed patients, and elderly 
controls. *p -" 0.05, different from AD patients and controls. 
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Table 3. Baseline Thyroid Function Tests and Ratings on Patients with Blunted TSH Response 
( A m a x T S H  <~ 7 p . lU /ml )  versus Nonblunted TSH Response ( A ~ T S H  > 7 t d U / m l y '  
Global 
AmaxTSH b TSH T4 FT ,  T3 Deterioration 
(~xlU/ml) (pdU/ml) (ttg/di) (ng/di) (ng/dl) Scale 
Alzheimer's 
Blunted (n = II) 5.0 ± 1.8 2.1 ,4- 1.5 8.2 ± 0.8 1.5 ± O.Y 123.1 ~ 38,2 
Nonblunted (n = 29) 15.4 ± 6.8 2.8 - 1.5 7.7 ± 1.3 i .3  ± 0.3 126.9 ± 26..6 
Depressed 
Blunted (n = 7) 4.0 "+" 1.9 1,7 ± 0.8 ~ 8.9 _+ 1.3 1.9 "¢" 0 ,2  d 123.9 "*- 23,9 
Nonblunted (n = 10) 9.6 +- 2.7 2.9 .4- 0.9 8.6 -- 1.8 ! ,6  "*" 0 ,2  117,3 "4" 25,5 
4.8 ± 1.0 ~ 
4.3 ± 0.9 
Hamilton 
(I 7 item) 
25.3 ~" 9.8 
21.5 ± 7.2 
'~Data are expressed as mean -.- SD. 
bThe maximal elevation of TSH after TRH administration minus baseline TSH. 
'p < 0.05 
dp <o . ! .  
B 
In the group of AD patients, AmaxTSH correlated significantly with baseline TSH (r 
= 0.51,  p < 0.001,  n = 37), I"4 (r = - 0 . 3 9 ,  p < 0 .02,  n = 37), and FT4 (r = 
- 0 . 5 2 ,  p < 0.001,  n = 40). AD patients with a blunted as compared with a nonblunted 
TSH response tended to be more severely demented as measured by the GDS (Table 3) 
and the Global Functional Impairment Scale (blunters = 8.9 ± 2.0, nonblunters = 6.9 
-+ 1.8; t = - 2 . 5 ,  p < 0 .01,  df = 29). AmaxTSH did not correlate with measures of  
depression. T3 correlated with the Global ratings of  depression (r = 0.49,  p < 0.01,  n 
26), anxiety (r = 0.42, p < 0.03,  n = 26), and sadness (r = 0 .47,  p < 0.02,  n 
= 26). FT4 and CSF MHPG correlated at a trend level of  significance (r = 0.33,  p < 
0.1, n = 25). Of the severity and behavioral measures, CSF MHIK; correlated at a trend 
level of significance with two measures of dementia severity, the CDR (r = 0.34,  p < 
0.07, n = 29) aM the GDS (r = 0.36,  p < 0.06,  n = 28). There were no correlations 
between AmaxTSH and CSF monoamine metabolites or CSF SH.  
Table 4. Gender Differences in TSH Response and Baseline Thyroid Function Tes t s  ~ 
Blunted TSH b AmaxTSH TSH "!"4 FT,, T3 
( tdU/ml)  ( tdU/ml)  (tdU/rnl) (p,g/dl) (ng/dl) (ng/di) 
Alzheimer's 
Male 5/25 (20.0%) 13,6 ± 7.6 ~ 2.6 _+ ! .3 7.6 ± 1.3 ! .4 .4- 0.3 123.4 _ 23.5 
Female 6/15 (40,0%) ! ' . 4  __ 7.3 2,6 ± 1,8 8.1 ± 1,0 1.3 -+ 0.2 122.5 ± 29.4 
Depressed 
Male 5/8 (67 ~%) 5.3 _ 3.1 2,3 -4- 1.1 7.5 ± i .4  i ,8 ± 0.4 113.2 _+ 17.5 
Female Z~, (33.3%) 8.7 ± 3.3 d 2.5 _+ 1.1 9 .6  ± 1.0 !.8 ± 0,2 125.6 ± 28.3 
Normals 
Male 1/9 (11.1%) 9.6 ± 3.6 e 2.9 & 1,0 7.5 ± 1.2 1.4 _ 0.3 127.4 ± 21.9 
Female 0/5 17.8 ± 6,7 3 1 ± 1,0 7.7 ± 1.4 ! .4 _+ 0.5 101.8 _ 6.4 
~Data are expressed as mean _+ SD. 
bAmaxTSH ~< 7 p.IU/ml. 
Cp < 0.05 different from depressed men. 
dp < 0,05 different from female controls. 
ep < 0.05, different from female controls. 
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In the AD patients with a presenile as c~mpared with senile onset of symptoms, there 
was no difference in AmaxTSH or baseline TFT~. Age correlated with AmaxTSH (r  = 
-0 .37 ,  p < 0.02) within the group of AD patients, and not w i ~  the major depression 
or control groups. Within the AD group, age and AmaxTSH correlated significantly for 
men (r = - 0 . 4 6 ,  p < 0.02); for women the relationship was not significant (r  - - 0 . 2 2 ,  
p < 0.44). 
Within the group of depressed patients, there were no correlations among ~ a s u r e s  
of depression, CSF monoamine metabolites, or CSF SLI and ~maxTSH or other thyroid 
measures. Within the group of depressed patients with a blunted TSH response, &'naxTSH 
correlated significantly only with baseline TSH (r  = 0.73, p < 0.05, n = 8). In the 
group of normal controls (excluding the one with a blunted response), there were no 
correlations between AmaxTSH and baseline TITs. 
Discussion 
Our finding of an increased rate of blunting on the TRH stimulation test and a lower 
mean &maxTgH in patients with major depression as compa,'ed with normals is consistent 
with the findings of most previous studies (Loosen 1987). A trend towards an increase 
in the rate of blunted responses in patients with AD is consistent with some (Sunderland 
et al 1985; Thomas et al 1987) but not all prior studies (El S o b ~  et al 1986; P e a ~ y  
et al 1986; Lampe et al 1988; Franceschi et al 1988; Dysken et al 1990). Reasons for 
such discrepant results may include the heterogeneity of patients with AD, the study of 
patients at different stages of the illness, the small number of patients used in some of 
the studies, and the inclusion of subjects w,th slight baseline TFT abnormalities. Also, 
some studies included only male subjects (Lampe et al 1988; Peabody et al 1986), and 
men have generally been shown to have a lower AmaxTSH than women with age (Snyder 
and Utiger 1972; Sunderland et al 1985; Targum et al i989; Dysken et al i990), therefore 
making any differences between AD and control subjects more difficult to discern. 
In our study, the AD patients with a blunted TSH response were more severely 
demented as measured by the GDS (at a trend level of significance) and the Global 
Functional Impairment Scale (p < 0.01) than those with a nonblunted response. We had 
previously reported a trend towards a correlation between increased dementia severity 
and TSH blunting in a different patient group (Sunderland et al 1985), though other 
studies have not found such a relationship (Franchesi et al i988; ~ s k e n  et al i ~ ) .  
In our study, as in most prior studies, no correlation was found between c l~ca l  
measures of depression and AmaxTSH (Loosen 1987). Consistent with our ~d ings ,  
depressed patients with a blunted TSH response have been shown in prior studies to have 
a lower basal TSH compared with patients whose response is normal or increased (Loosen 
1987). Also consistent with some prior studies, the depressed patients had a higher mean 
1"4 level (and FT4 level, significant at the trend level) than the AD and the control patients 
(Kirkegaard and Faber 1986). In the AD group, those wffb a blunted response had an 
increased FT4, as shown previously in a smaller sample (Sunderland et al 1985), indicating 
normal feedback inhibition. Hypothalamic neuropathology has been documented in AD 
(Ishii 1966; McDuff and Sumi 1983), but most studie~ have not found a s i~f ican t  change 
in TRH concentration in AD brain (Yates et al 1983; Nemeroff et aI 1989) or CSF 
(Nemeroff, personal communication), though one study did report a decrease in CSF 
TRH (Oram et al 1981). Interestingly, in one small study, TRH concentration in the 
amygdala of AD patients tended to correlate with senile plaque count (r = - 0 . 6 7 ,  p < 
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0. I, n = 7) (Biggins et al 1983), which has been shown to be related to dementia severity 
(Blessed et al 1968). 
In our study, within the group of AD patients, women had a rate of blunting twice 
that of men though this was not statistically significant; there were no gender differences 
in baseline TFTs or other variables. Our findings are most consistent with those of one 
other report, in which no difference between genders was found (El Sobky et al 1986). 
This is of interest in that a significant age-related decrease in AmaxTSH in men relative 
to age-matched women (Snyder and Utiger 1972; Sunderland et al 1985; Targum et al 
1989) was not seen in these studies in AD subjects, nor in depressed patients in the 
present study, though age correlated significantly with AmaxTSH within the group of 
male AD patients. Reasons for these findings are unknown. One study of AD patients 
found that men had a decreased AmaxTSH response as compared with women (Dysken 
et al 1990). 
We found no correlations between AmaxTSH or ~ l i n e  TSH and CSF monoamine 
metabolite levels in any of the subject groups. Prior studies of associations between TSH 
response and measures of monoamine metabolism in depressed patients have produced 
conflicting results (Loosen 1987). In general, evidence from human and animal studies 
indicate that norepinep~ne has a stimulatory role and serotonin an inhibitory role in 
hypothalamic-pituitary-thyroid axis regulation (Loosen 1987). 
In the present study, FT4 correlated at a trend level of significance with CSF MHPG 
within the group of AD patients, which is consistent with a stimulatory effect of nor- 
epinephrine on the thyroid axis and the adjunctive role of thyroid hormones on norad- 
renergic function (Nemeroff and Evans 1989). Interestingly, in our group of AD patients, 
T3 and I"4 correlated withmeasures of depression and anxiety. 1"3 is sometimes added to 
augment antidepressant medication response, presumably through interactions with cate- 
cholamines (Nemeroff and Evans 1989). 
We found no correlations between AmaxTSH or baseline TSH and CSF SLI. So- 
matostatin has been shown to have an inhibitory effect on TRH-stimulated TSH release, 
though no study to date has shown a relationship between CSF SLI and blunted TSH 
response (Loosen 1987). 
In summary, the blunted TSH response in some AD patients is consistent with increased 
inhibition of TSH by relatively high levels of FT4 (Loosen and Prange 1982). The feedback 
regulation of thyroid hormones appears then to be intact. Why these patients have increased 
FT4 levels is unknown; the mechanism may involve decreased feedback or increased 
stimulation of thyroid hormones by some other substance, such as norepinephrine. This 
would be consistent with our finding of a positive correlation between FT4 and CSF 
MHPG, which indicates that increased norepinephrine could be contributing to increased 
FT4 levels. Also, patients with a blunted TSH response had significantly higher ratings 
of dementia severity, and dementia severity correlated positively with CSF MHPG, 
consistent with the findings of Raskind et al (1984). 
In the patients with major depression, our findings are consistent with chronic hy- 
persecretion of TRH as an etiology for blunted TSH responses, in that those with a blunted 
response had a low basal TSH that could be secondary to TSH receptor desensitization 
(Kirkega~rd et al 1979, Banki et al 1988). Also, TRH itself stimulates thyroid hormone 
release (Griffiths 1985), so TRH hypersection could have contributed to increased T4 and 
FT4 levels. Increased thyroid hormone levels would further lower TSH levels by feedback 
inhibition. 
A blunted TSH response to TRH in some depressed a~d a subgroup of AD patients 
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appears to be related to different clinical factors in these groups (to dementia severiW 
and possibly age and gender in the AD patients) and to involve some different e t i o l ~  
factors. Further studies utilizing the TRH stimulation test and other neuroeMocrine tests 
may help to distinguish diagnostic subgroups and to clarify relationships among different 
neuropsychiatric illnesses. 
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